DUBLIN–(BUSINESS WIRE)–The “Investor Series: Opportunities in Women’s Digital Health Market” report has been added to ResearchAndMarkets.com’s offering.
Digital health is a broad concept that encompasses telemedicine, teleconsultation, remote monitoring, connected devices, digital health platforms and health applications. The outbreak of COVID-19 pandemic has propelled the usage of digital technologies in order to receive healthcare, remotely. The revolutionary developments in digital health have transformed medicine and biomedical science as well as promoted early disease diagnosis and treatment.
In addition, several FemTech startups are focused on the development of products or offering services to women of all age groups dealing with issues related to pregnancy, periods and menopause. Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women’s digital health domain have witnessed a surge in the investment activity, with capital investments worth more than USD 3 billion over the past few years.
This has enabled the overall FemTech business to flourish. It is worth noting that, NC Birth Control, developed by Natural Cycles, was the first application to receive approval from US FDA in 2018 and is CE marked in Europe. This application can be used as a method of contraception and to track menstrual cycles, regularly. Subsequently, in 2021, various other women’s digital health solutions received US FDA approvals, including Ava Fertility Tracker (first approved fertility tracking wearable) and Clue (period tracking and birth control app).
Currently, more than 200 women’s digital health solutions, including applications / software, wearable devices, and services have been marketed / are under development with applications across various therapeutic areas including, reproductive health / fertility, menstrual cycle, general wellness, pelvic care and fetal health. These digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population.
In addition, by advocating more personalized and meaningful treatment for women, employers may advance health equity and aid in the eradication of healthcare inequities. Given the increasing research efforts and active involvement of investors, we anticipate the development of a variety of applications and devices focused on improving women’s health, in the coming years. Further, taking into consideration both the historical and contemporary scenarios, we believe that the women’s digital health market presents lucrative investment opportunities for both short and long term investors.
Scope of the Report
The report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:
- An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain.
- A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.
- An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
- An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value.
- A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
- A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment.
- An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
- A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.
- A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks).
- A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with the women’s digital health market, over the coming decades. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity within the women’s digital health market have further been segmented across type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Companies Mentioned
- #ANGELS
- 14W
- 15th Rock
- 1776 Ventures
- 1984 Ventures
- 2048 Ventures
- 3L
- 415 Ventures
- 4FO Ventures
- 500 Global
- 500 Startups
- 8VC
- 9Unicorns
- a thousand colibris
- AH trust
- Aavia
- Accorded
- ACME Capital
- Act One Ventures
- Activision Blizzard
- Acumen
- Ad Astra Ventures
- Adaptive Health Capital
- Aindra Systems
- Alife
- App Basic
- Apricity
- Arbor
- Arboretum Ventures
- ArlanWasHere Investments
- Artesian
- Ascension Ventures
- Aspivix
- Asset Management Ventures
- Astia Angels
- Astinno
- ATH Holding Company
- Atlantic Bridge
- Atlantic Health System
- Atlantic Therapeutics
- AtlasV
- Atomico
- Atreyu
- Aurora Health Care
- Ava
- Avaana Capital
- Avestria Ventures
- Awesome People Ventures
- aws Grunderfonds
- Axilor
- Baby2Body
- Babyscripts
- Backstage Capital
- Baker Bros. Advisors
- balance
- Balderton
- Band of Angels
- Banner Health
- BBG Ventures
- Beacon Angels
- BEENEXT
- Begin Capital
- Bellabeat
- Bethnal Green Ventures
- BGF
- Bia Med
- Bill & Melinda Gates Foundation
- Biowink
- Black Capital
- Black Pearl Global Investments
- Blackbird
- BlackRock
- Bloody Health
- Bloomer Tech
- Bloomlife
- Bloomth
- Blossom Capital
- Blue Cross Blue Shield of Massachusetts
- Blue Ocean Ventures
- Blue Ox Healthcare Partners
- BlueRun Ventures
- Blume Equity
- BNP Paribas
- Bolt Ventures
- BOND
- Bonnier Ventures
- Bonzun
- Borski Fund
- Bose Ventures
- BoxGroup
- Bramalea Partners
- Bread and Butter Ventures
- breathe ilo
- BrightCap Ventures
- Brilliantly
- Broadway Angels
- btov
- Business Angels Club Berlin-Brandenburg
- Business Angels Switzerland
- B-wom
- Cambia Health Solutions
- Cambridge Digital Health
- Canaan
- Candlelit
- Canopie
- Capier Investments
- Capital Angel Network
- Care4Cute
- CareSignal
- Carnrite Ventures
- Carrot Fertility
- Casdin Capital
- Catalyst Health Ventures
- Cayaba Care
- CG Health Ventures
- Chemo
- Cherubic Ventures
- Chiaroscuro Foundation
- Chione
- Chiratae Ventures
- Chorus Health
- Chrysalis
- Cigna Ventures
- Claritas Capital
- Clementine
- CM-CIC Innovation
- Coelius Capital
- Collaborative Fund
- Colle Capital
- Combine
- Commonfund
- Company Ventures
- Compound
- Connect
- Connecticut Innovations
- Core Innovation Capital
- Cormorant Asset Management
- Coroflo
- Correlation Ventures
- Cortado Ventures
- Crescent Ridge
- CrunchFund
- CRV
- CU Healthcare Innovation Fund
- Deerfield
- Define Ventures
- Development Bank of Wales
- Digitalis Ventures
- DigiTx Partners
- DilenyTech
- Domain Associates
- Downing Ventures
- Dragoneer Investment Group
- Draper Associates
- Dream Incubator
- DSM Venturing
- Earlybird Venture Capital
- Ease Healthcare
- Easton Capital Investment Group
- Echo Health Ventures
- EIT Health
- ElaWoman
- Elda Health
- Eldridge
- Eli Health
- Elidah
- EloCare
- e-L?vu Health
- Elvie
- Elysium Venture Capital
- Embr Labs
- Embria
- Emme (a part of SimpleHealth)
- Endeavour Vision
- Endodiag
- Endometrix
- ENSE Group
- Enterprise Ireland
- Enzia Ventures
- Episcopal Health Foundation
- EQT Ventures
- eQventure
- Established Ventures
- European Commission
- European Innovation Council and SMEs Executive Agency (EISMEA)
- Evernow
- Exandus
- Exor
- F Cubed
- Felix Capital
- Female Founders Fund
- Femcare Fertility
- Femcy
- FemHealth Ventures
- FEMM
- Femna Health
- Femometer
- FemTech Healthcare
- FemX
- fermata
- Ferne Health
- FetoLife
- Firestartr
- First Round Capital
- FirstCheck Africa
- FirstMark
- Fizimed
- Flanders Innovation and Entrepreneurship (VLAIO)
- Flare Capital Partners
- Flint Capital
- Flo Health
- Flo Living
- Floka
- Foothill Ventures
- Forerunner
- Formation 8
- Fors Marsh
- Fortunis Capital
- Foundation for Technological Innovation
- Founders Fund
- Foview
For more information about this report visit https://www.researchandmarkets.com/r/n32pr9-series?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
